SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

SH5-07

Item No. 36818

CAS Registry No.: 1456632-41-9
Formal Name: 4-[[(4-cyclohexylphenyl)methyl][2-[methyl[(2,3,4,5,6-pentafluorophenyl)sulfonyl]amino]acetyl]amino]-N-hydroxy-benzamide
MF: $C_{29}H_{28}F_5N_3O_5S$
FW: 625.6
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SH5-07 is supplied as a solid. A stock solution may be made by dissolving the SH5-07 in the solvent of choice, which should be purged with an inert gas. SH5-07 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of SH5-07 in these solvents is approximately 3 mg/ml.

Description

SH5-07 is a STAT3 inhibitor (K_i = 10.46 µM).[1] It is selective for STAT3 over STAT1 (K_i = >100 µM). SH5-07 prevents constitutively active STAT3 DNA binding in NIH3T3 fibroblast nuclear extracts (IC_{50} = 3.9 µM).[2] It is cytotoxic to AR230 and imatinib-resistant AR230 chronic myeloid leukemia (CML) cells (IC_{50}s = 8.1 and 7 µM, respectively) and a variety of glioblastoma cancer stem cells (CSCs; IC_{50}s = 0.195-1.12 µM).[2,3] SH5-07 reduces tumor growth in MDA-MB-231 breast cancer and U-251MG glioblastoma mouse xenograft models when administered at doses of 3 and 5 mg/kg, respectively.[2] It is also active against *T. gondii* when used at a concentration of 5 µM.[4]

References

1. Haftchenary, S., Luchman, H.A., Jouk, A.O., *et al.* Potent targeting of the STAT3 protein in brain cancer stem cells: A promising route for treating glioblastoma. *ACS Med. Chem. Lett.* **4(11)**, 1102-1107 (2013).
2. Yue, P., Lopez-Tapia, F., Paladino, D., *et al.* Hydroxamic acid and benzoic acid-based STAT3 inhibitors suppress human glioma and breast cancer phenotypes *in vitro* and *in vivo*. *Cancer Res.* **76(3)**, 652-663 (2016).
3. Ali, A.M., Gómez-Biagi, R.F., Rosa, D.A., *et al.* Disarming an electrophilic warhead: Retaining potency in tyrosine kinase inhibitor (TKI)-resistant CML lines while circumventing pharmacokinetic liabilities. *ChemMedChem* **11(8)**, 850-861 (2016).
4. Li, S., Ying, Z., Xue, Y., *et al.* Effects of different drugs and hormone treatment on Toxoplasma gondii glutathione S-transferase 2. *Parasit. Vectors* **15(1)**, 461 (2022).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM